title: Alendronate for the treatment of osteoporosis in men.
abstract: BACKGROUND
  Men have higher rates of osteoporosis and suffer fragility fractures more often than previously believed. Fracture-related morbidity and mortality in men is substantially higher than in women.
  
  
  OBJECTIVE
  To investigate alendronate for treating osteoporosis in men.
  
  
  METHODS
  Search limited to 'men' and 'English'; keywords were 'osteoporosis' or 'bone density' or 'fracture' and 'alendronate'.
  
  
  CONCLUSIONS
  Alendronate is an amino-bisphosphonate with proved efficacy for increasing bone mineral density in men with idiopathic or secondary osteoporosis and has demonstrated an ability to prevent vertebral fractures in men with low bone mass. There are trends for alendronate to decrease the risk of non-vertebral fracture, but larger trials are needed to conclusively establish this benefit. Alendronate is a well-tolerated and comparatively safe drug with an attractive once-a-week dosing regimen.
authors.affiliation: University of Saskatchewan, Saskatoon, SK, Canada. olszynski@webster.sk.ca
authors.forename: W P
authors.initials: WP
authors.lastname: Olszynski
authors.forename: K S
authors.initials: KS
authors.lastname: Davison
mesh_terms: D019386:Alendronate / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D050071:Bone Density Conservation Agents; D005938:Glucocorticoids; D019386:Alendronate